Hematologic Oncology

Parsaclisib Yields Encouraging Clinical Activity in Marginal Zone Lymphoma

Expert discuss their expectations for research and drug development in oncology in the new year.

$BTK inhibitor–naïve patients with relapsed/refractory marginal zone Lymphoma achieved rapid and durable responses with single-agent parsaclisib, as demonstrated in the CITADEL-204 trial.$

By Erica DiNapoli

1-Year DFS Rates Similar Between Ibrutinib and Placebo Following Ibrutinib/Venetoclax in CLL

Tycel Phillips, MD, highlighted the key findings of the phase 2 CITADEL-204 trial.

By Erica DiNapoli

Adult Nonmalignant Hematology Is an Endangered Field That Merits Protection

William G. Wierda, MD, PhD, discusses the latest CAPTIVATE findings in patients with chronic lymphocytic leukemia.

By Jennifer R. Green, MD

PANORAMA 3 Study Resets Expectations for Panobinostat in Multiple Myeloma

The scope of adult nonmalignant hematology can be broad and includes thrombotic and hemorrhagic disorders, transfusion medicine, hemoglobin disorders including sickle cell disease and thalassemia, anemia, thrombocytopenia, leukocytosis, leukopenia, and disorders of iron metabolism.

Andrew Spencer, MD, MBBS, FRACP, FRCPA, of The Alfred Hospital

By Caroline Seymour

Treating Young Adult Patients With Philadelphia Chromosome-Negative ALL

Andrew Spencer, MD, MBBS, FRACP, FRCPA discusses the significance of the PANORAMA 3 study in multiple myeloma.

By Richard M. Stone, MD, Dana-Farber Cancer Institute
Ryan D. Cassaday, MD, University of Washington/Fred Hutch

Prognostic Significance of IDH Mutations in AML

By Harry P. Erba, MD, PhD, Duke University School of Medicine
Alexander E. Perl, MD, University of Pennsylvania

FLT3 Testing for Treatment of AML

By Harry P. Erba, MD, PhD, Duke University School of Medicine
Alexander E. Perl, MD, University of Pennsylvania

Dr. Hobbs on the Role of Molecular Testing to Determine Resistance in CML

Gabriela Hobbs, MD, of Massachusetts General Hospital

By Gabriela S. Hobbs, MD

Dr. Jabbour on Selecting Ponatinib After Second-Generation TKI Failure in CML

Gabriela Hobbs, MD, discusses the role of molecular testing to determine resistance in chronic myeloid leukemia.

Elias Jabbour, MD, of The University of Texas MD Anderson Cancer Center

By Elias Jabbour, MD

Remaining ECHELON-2 Questions Spark Novel Research Efforts in PTCL

Elias Jabbour, MD, discusses selecting ponatinib after failure of a second-generation TKI therapy in chronic myeloid leukemia.

Jakub Svoboda, MD, of Abramson Cancer Center of Penn Medicine

By Jessica Hergert

FDA Grants Priority Review to Narsoplimab for HSCT-TMA

Jakub Svoboda, MD, discusses the results of the ECHELON-2 trial and explained where clinical research is headed in peripheral T-cell lymphoma.

By Kristi Rosa

Pursuing Pairings of Targeted Agents and HMAs in AML

January 19, 2021 — The FDA has granted priority review to the biologics license application for narsoplimab for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy.

Alison R. Sehgal, MD, of UPMC Hillman Cancer Center

By Caroline Seymour

Frontline Treatment Options in Chronic Lymphocytic Leukemia

Alison R. Sehgal, MD, discusses some of the novel approaches that have been adopted into practice and ongoing research building on the advances that have been made with targeted therapy.

By Stephan Stilgenbauer, MD, Ulm University
Paolo Ghia, MD, Phd, Universita Vita-Salute San Raffaele

Guidelines for Chronic Lymphocytic Leukemia

The experts comment on first-line treatment options in patients with chronic lymphocytic leukemia.

By Stephan Stilgenbauer, MD, Ulm University
Paolo Ghia, MD, Phd, Universita Vita-Salute San Raffaele

Treatment Approaches in Mantle Cell Lymphoma

Dr Brown and Dr Ghia discuss the European Society for Medical Oncology [ESMO] and International Workshop on Chronic Lymphocytic Leukemia [iwCLL] recommended guidelines in assessing and treating chronic lymphocytic leukemia.

By John P. Leonard, MD, New York-Presbyterian/Weill Cornell Medicine
Krish Patel, MD, Swedish Medical Center

Accurately Diagnosing Mantle Cell Lymphoma

By John P. Leonard, MD, New York-Presbyterian/Weill Cornell Medicine
Krish Patel, MD, Swedish Medical Center

Capitalizing on Cellular Therapies in Lymphoma and Myeloma

By OncLive Staff

Could Orca-T Unlock New Path of Reduced Mortality, Prevent GVHD Posttransplant?

In our exclusive interview, Dr. Kansagra, Dr. D’Souza, and Dr. Dholaria provided an in-depth look into the current state of cellular therapy in hematologic malignancies, the benefits and drawbacks of approved and investigational products, and new constructs for CAR T in multiple myeloma and lymphoma.

Steven Devine, MD, of Center for International Blood and Marrow Transplant Research

By Gina Mauro

Dr. Cortes on the Future of Ponatinib in CML Treatment

Steven Devine, MD, discusses the non-relapse mortality data with Orca-T and how this technologic approach is changing how providers approach patients with hematologic malignancies following transplant.

Jorge E. Cortes, MD, of the Georgia Cancer Center at Augusta University

By Jorge E. Cortes, MD

DREAMM-2 Trial Regimen Safety Profile

Jorge E. Cortes, MD, discusses the future of ponatinib in the treatment of patients with chronic myeloid leukemia.

By Sagar Lonial, MD, FACP, Winship Cancer Institute of Emory University
Asim V. Farooq, MD, University of Chicago Medical Center

DREAMM-2 Trial Efficacy Data and Recent FDA Approval

By Sagar Lonial, MD, FACP, Winship Cancer Institute of Emory University
Asim V. Farooq, MD, University of Chicago Medical Center

Rapid Readouts: Efficacy of Novel Targeted Therapies Post-MURANO Study

By Matthew S. Davids, MD, MMSc, Dana-Farber Cancer Institute

Rapid Readouts: The Phase 1/2 ANCHOR Trial for Melphalan Flufenamide in Relapsed/Refractory Multiple Myeloma

$Rapid Readouts: The Phase 1/2 ANCHOR Trial for Melphalan Flufenamide in Relapsed/Refractory Multiple Myeloma$

By Peter Voorhees, MD, Atrium Health